Phio Pharmaceuticals
PHIO
6 hedge funds and large institutions have $220K invested in Phio Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.
3% more capital invested
Capital invested by funds: $213K → $220K (+$6.5K)
0.34% more ownership
Funds ownership: 0.04% → 0.38% (+0.34%)
40% less funds holding
Funds holding: 10 → 6 (-4)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$83.5K |
| 2 |
Renaissance Technologies
New York
|
+$2.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$39K |
| 2 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$27.9K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$15.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$10K |
| 5 |
Two Sigma Investments
New York
|
-$8.33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $80K | +$2.27K | +43 | +3% |
|
|
2
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $80K | +$83.5K | +1,581 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $57.8K | -$15.3K | -289 | -20% |
|
|
4
UBS Group
Zurich,
Switzerland
| $1.16K | -$10K | -190 | -89% |
|
5
Morgan Stanley
New York
| $703 | – | – | – |
|
6
Wells Fargo
San Francisco,
California
| $45 | – | – | – |
|
7
BlackRock
New York
| $6 | – | – | – |
|
|
8
Geode Capital Management
Boston,
Massachusetts
| – | -$39K | -990 | Closed |
|
|
9
Cetera Investment Advisers
Schaumburg,
Illinois
| – | -$27.9K | -694 | Closed |
|
|
10
Two Sigma Investments
New York
| – | -$8.33K | -207 | Closed |
|
|
TSS
11
Two Sigma Securities
New York
| – | -$7.33K | -182 | Closed |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| – | -$2K | -48 | Closed |
|
PHIO Hedge Fund Activity: Q1 2023 in Review
6 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q1 2023, worth a combined $220K — up 3.1% from $213K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PHIO and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $83.5K. The largest seller was Geode Capital Management, exiting entirely with an estimated $39K sold.
- 6 institutional investors held Phio Pharmaceuticals (PHIO) as of Q1 2023, down from 10 in Q4 2022.
- Funds reported $220K of Phio Pharmaceuticals stock for Q1 2023, up 3.1% quarter-over-quarter.
- 1 fund opened new Phio Pharmaceuticals positions in Q1 2023 and 5 closed out, a net change of -4 holders.
- The largest Phio Pharmaceuticals buyer in Q1 2023 was Cambridge Investment Research Advisors, an estimated $83.5K added.
- The largest Phio Pharmaceuticals seller in Q1 2023 was Geode Capital Management, an estimated $39K sold.
Based on aggregated 13F filings for Q1 2023.